Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · REVELATION BIOSCIENCES, INC. (REVB)

Revelation Biosciences Q3 net loss widens to $3.3 million; cash falls to $9.1 million

Negative Impact 3 of 5 earnings Written later

Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.

Key points

  • Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
  • Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
  • Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
  • Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.

The filing

CompanyREVELATION BIOSCIENCES, INC. (REVB)
Form8-K, current report
Filed with the SECNov 5, 2026, 5:29 PM ET
Accession number0001193125-26-450210

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.